

DAFTAR PUSTAKA

1. Harsono AB. Kanker Ovarium: "The Silent Killer." *Indones J Obstet Gynecol Sci.* 2020;3(1):1-6.
2. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. In: *Seminars in Surgical Oncology*. Vol 19. Wiley Online Library; 2000:3-10.
3. Prat J, Oncology FC on G. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet.* 2014;124(1):1-5.
4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. In: *Database of Abstracts of Reviews of Effects (DARE): Quality-Assessed Reviews [Internet]*. Centre for Reviews and Dissemination (UK); 2002.
5. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, Van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. *Gynecol Oncol.* 1998;71(3):431-436.
6. Mousavi AS, Mazhari MM, Guilani MM, Ghaemmaghami F, Behtash N, Akhavan S. Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively? *World J Surg Oncol.* 2010;8(1):1-5.
7. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. *Am J Obstet Gynecol.* 1994;170(4):974-980.
8. Forstner R. Radiological staging of ovarian cancer: imaging findings and

contribution of CT and MRI. *Eur Radiol.* 2007;17(12):3223-3235.

9. Tentes AA, Tripsiannis G, Markakidis SK, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. *Eur J Surg Oncol.* 2003;29(1):69-73.
10. Jónsdóttir B, Lomnytska M, Poromaa IS, Silins I, Stålborg K. The peritoneal cancer index is a strong predictor of incomplete cytoreductive surgery in ovarian cancer. *Ann Surg Oncol.* 2021;28(1):244-251.
11. Lombardo Galera S, Espejo Herrera JJ, López Redondo C, Pérez Montilla ME, Muñoz Casares FC, Zurera Tendero LJ. Peritoneal Cancer Indexes in Ovarian Carcinomatosis: Correlation between CT and Intraoperative Results and Survival. *Is CT a Good Tool Correl Clin Surg 2016; 1.* 1209.
12. Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P. Ovarian cancer, the revised FIGO staging system, and the role of imaging. *Am J Roentgenol.* 2016;206(6):1351-1360.
13. Delgado-Barriga K, Medina C, Gomez-Quiles L, Marco-Domenech SF, Escrig J, Lluca A. CT Enterography for Preoperative Evaluation of Peritoneal Carcinomatosis Index in Advanced Ovarian Cancer. *J Clin Med.* 2022;11(3). doi:10.3390/jcm11030476
14. Henderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer: An Updated Evidence Review for the US Preventive Services Task Force [Internet]. Published online 2018.
15. Jónsdóttir B, Lomnytska M, Poromaa IS, Silins I, Stålborg K. The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer. *Ann Surg Oncol.* 2021;28(1):244-251. doi:10.1245/s10434-020-08649-6
16. Hural O, Mylyan Y, Fetsych M, Yarema R. The efficiency of CT at pre-

operative evaluation stage of PCI in patients with recurrent ovarian cancer. In: European Congress of Radiology-ECR 2017; 2017.

17. World Cancer Research Fund AIFCR. *Continuous Update Project. Ovarian Cancer 2014 Report.*; 2014.
18. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. NCCN guidelines insights: ovarian cancer, version 1.2019: featured updates to the NCCN guidelines. *J Natl Compr Cancer Netw.* 2019;17(8):896-909.
19. Saint John's Cancer Institute. *Ovarian Cancer.*; 2021.
20. Trihandini I, Nurrika D. Analisis ketahanan hidup lima tahun penderita kanker ovarium epithelial di Rumah Sakit Kanker Dharmais Jakarta. *Kesmas J Kesehat Masy Nas (National Public Heal Journal).* 2010;5(3):139-144.
21. Mok SC, Kwong J, Welch WR, et al. Etiology and pathogenesis of epithelial ovarian cancer. *Dis Markers.* 2007;23(5-6):367-376.
22. Franks S. Polycystic ovary syndrome. *N Engl J Med.* 1995;333(13):853-861.
23. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *J Turkish Ger Gynecol Assoc.* 2019;20(1):47.
24. World Cancer Research Fund. *Diet, Nutrition, Physical Activity and Cancer: A Global Perspective: A Summary of the Third Expert Report.* World Cancer Research Fund International; 2018.
25. Braat DDM. Diagnosis and management of ovarian disorders. *Eur J Obstet Gynecol.* 1997;2(72):217.
26. Lundberg FE, Johansson AL V, Rodriguez-Wallberg K, Gemzell-Danielsson K, Iliadou AN. Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study. *Eur*

J Epidemiol. 2019;34(11):1093-1101.

27. I. B. Rumbawa Pamaron. *Perbedaan Kadar Cancer Antigen-125 Dan Human Epididimis-4 Pada Kanker Ovarium Tipe Epitelial Stadium I, Stadium II Dan Stadium III.*; 2016.
28. Gubbels JAA, Felder M, Horibata S, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. *Mol Cancer.* 2010;9(1):1-14.
29. Rumack CM, Levine D. *Diagnostic Ultrasound.* Elsevier Health Sciences; 2017.
30. Jordan SJ, Wilson LF, Nagle CM, et al. Cancers in Australia in 2010 attributable to and prevented by the use of combined oral contraceptives. *Aust NZ J Public Health.* 2015;39(5):441-445.
31. Fagan P, Banerjee S, Barton D, et al. 557 Peritoneal cancer index (PCI) as a predictor of completeness of cytoreduction at primary and interval debulking surgery in advanced ovarian cancer. Published online 2020.
32. Torre L, Trabert B, DeSantis C, et al. Ovarian cancer statistics. *CA Cancer J Clin.* 2018;68(4):284–296.
33. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. *Int J Womens Heal.* 2019;11:287-299.
34. Arora N, Talhouk A, McAlpine J, Law M, Hanley G. Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. *BMC Cancer.* 2018;18(1):1039.
35. Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. *PLoS*

One. 2018;13(10):e0205000.

36. Ellwanger B, Schüler-Toprak S, Jochem C, Leitzmann MF, Hansjörg B. Anthropometric factors and the risk of ovarian cancer: A systematic review and meta-analysis. *Cancer Rep*. 2022;5(11):e1618. doi:10.1002/cnr2.1618
37. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer viewpoint of the IARC working group. *N Engl J Med*. 2016;375(8):794-798.
38. Karamouza E, Glasspool R, Kelly C, et al. CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. *Cancers (Basel)*. 2023;15(6):1823.
39. Pelayo M, Pelayo-Delgado I, Sancho-Sauco J, et al. Comparison of Ultrasound Scores in Differentiating between Benign and Malignant Adnexal Masses. *Diagnostics*. 2023;13(7):1307.
40. Lomnytska M, Karlsson E, Jonsdottir B, et al. Peritoneal cancer index predicts severe complications after ovarian cancer surgery. *Eur J Surg Oncol*. 2021;47(11):2915-2924.
41. Asp M, Malander S, Wallengren N, et al. The role of computed tomography in predicting peritoneal carcinomatosis and upfront surgery outcome in advanced ovarian cancer. Published online 2020.
42. Yaznil MR, TJOKROPRAWIRO BA, Fauziah D. Hubungan Peritoneal Carcinomatosis Index dan Predictive Index Value Fagotti dengan Kadar Serum Fatty Acid Binding Protein 4 pada Kanker Ovarium Epitel Stadium Lanjut. *Indones J Cancer*. 2017;11(3):97-104.
43. Lluca A, Escrig J, Serra-Rubert A, et al. Prognostic value of peritoneal cancer index in primary advanced ovarian cancer. *Eur J Surg Oncol*. 2018;44(1):163-169.

44. Elzarkaa AA, Shaalan W, Elemam D, et al. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study. *J Gynecol Oncol*. 2018;29(4).
45. Gu B, Xia L, Ge H, Liu S. Preoperative PET/CT score can predict complete resection in advanced epithelial ovarian cancer: a prospective study. *Quant Imaging Med Surg*. 2020;10(3):743.
46. Verri D. Pre-operative evaluation in advanced ovarian cancer: is ultrasound ready to replace computed tomography? *Int J Gynecol Cancer*. 2019;29(2):225-226.
47. Rancourt C, Matte I, Lane D, Piché A. The role of MUC16 mucin (CA125) in the pathogenesis of ovarian cancer. *Ovarian cancer basic Sci Perspect Vol*. 2012;1:67-84.
48. Quaranta D, Lambaudie E, Heinnemann M, Houvenaeghel G, Chéreau E. Evaluation of single-port laparoscopy for peritoneal carcinomatosis assessment in advanced ovarian cancer. *Eur J Obstet Gynecol Reprod Biol*. 2014;181:60-65.
49. Chéreau E, Ballester M, Selle F, Cortez A, Daraï E, Rouzier R. Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. *Am J Obstet Gynecol*. 2010;202(2):178-e1.
50. He C, Thapa N, Wang Y, et al. Prognostic significance of log (CA125)/PCI for the resectability of epithelial ovarian cancer: a retrospective study. *Cancer Manag Res*. 2020;12:2223.
51. Lee EYP, An H, Tse KY, Khong PL. Molecular Imaging of Peritoneal Carcinomatosis in Ovarian Carcinoma. *Am J Roentgenol*. 2020;215(2):305-312.

52. Climent MT, Serra A, Gilabert-Estellés J, Gilabert-Aguilar J, Lluca A. Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in gynecologic malignancies. *J Clin Med.* 2021;10(12):2553.
53. Lampe B, Kroll N, Piso P, Forner DM, Mallmann P. Prognostic significance of Sugarbaker's peritoneal cancer index for the operability of ovarian carcinoma. *Int J Gynecol Cancer.* 2015;25(1).



